CD164 and neoplasm: Further closely related to drug metabolism, excretion, and pharmacodynamics, GSEA analysis also revealed that CD164 modulates pathways, including AMPK signaling, butyrate metabolism, and circadian rhythm, so influencing tumor progression (Figure 3C).